Differential effects of intrathecally administered N- and P-type voltage-sensitive calcium channel blockers upon two models of experimental mononeuropathy in the rat

Yamamoto, Tatsuo; Sakashita, Yoshihiko

doi:10.1016/s0006-8993(98)00306-0

Cited by 66 publications

(40 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In neuropathic pain models, intrathecal administration of ω-agatoxin IVA to block P/Q-type channels has no effect on mechanical allodynia and thermal hyperalgesia. 41,55 Deleting Ca V 2.1 in mice results in no change in nociceptive responses to non-injurious noxious thermal stimuli. 56 These data suggest an anti-nociceptive role of P/Q-type channels.…”

Section: L-type Voltage-gated Calcium Channelsmentioning

confidence: 99%

Calcium channel functions in pain processing

Park¹,

Luo²

2010

Channels

120

103

View full text Add to dashboard Cite

Section: L-type Voltage-gated Calcium Channelsmentioning

confidence: 99%

Calcium channel functions in pain processing

Park¹,

Luo²

2010

Channels

120

103

View full text Add to dashboard Cite

“…Effects of intrathecally administered N-type and P-type VSCC blockers on the level of thermal hyperalgesia have been compared in two neuropathic pain models: the chronic constriction injury model and the partial sciatic nerve injury model [18]. N-type, but not P-type, VSCC blockers attenuated the level of thermal hyperalgesia induced by chronic constriction injury in a dose-dependent manner.…”

Section: In Vivo Studiesmentioning

confidence: 99%

An evaluation of intrathecal ziconotide for the treatment of chronic pain

Jain¹

2000

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Ziconotide, the synthetic form of cone snail peptide pi-conotoxin MVIIA, is a neurone-specific N-type calcium channel blocker with an analgesic and neuroprotective effect. Intrathecal ziconotide has been recommended for approval by the FDA for the management of chronic pain. Spinally administered ziconotide produces analgesia by blocking neurotransmitter release from primary nociceptive afferents and prevents the propagation of pain signals to the brain. It has an advantage over intrathecal morphine in that there is no development of tolerance after prolonged use. Systemic toxicity is considerably reduced by administration of smaller doses intrathecally and selective delivery to the site of action in the nervous system. Nevertheless, there are neurological adverse effects due to delay in clearance of ziconotide from the neural tissues. Overall, ziconotide has a favourable risk/benefit ratio with advantages over several currently available intrathecal therapies for pain.

show abstract

“…226 In mice the tactile allodynia resulting from vincristine was also not blocked by -agatoxin IVA. 68…”

Section: Pain Behaviormentioning

confidence: 97%

“…24,33 In CCI ligation models in rats, thermal hyperalgesia was significantly attenuated. 226 In diabetic rats, intrathecal administration of SNX-239, at a dose well below that which produced motor problems, showed complete suppression of mechanical allodynia. 28 In mice, intrathecal -conotoxin GVIA produced a dose-dependent reversal of the vincristine-induced allodynia.…”

Section: Pain Behaviormentioning

confidence: 99%